EAT
0.02
900%
XST
0.03
-40%
PIL
0.006
200%
HYD
0.014
-39.1%
TRI
0.031
158.3%
ENT
0.006
-33.3%
AGD
0.115
144.7%
ELS
1.345
-32.8%
CUF
0.04
135.3%
EOS
5.39
-29.9%
HWK
0.035
105.9%
EQS
0.012
-29.4%
AYM
0.006
100%
ERD
1.7
-29.2%
SKN
0.006
100%
T3D
0.085
-29.2%
NVA
1.535
98.1%
DTM
0.005
-28.6%
RML
0.086
91.1%
SPQ
0.01
-28.6%
CNJ
0.013
85.7%
1MC
0.05
-26.5%
RDN
0.009
80%
ATC
0.04
-25.9%
EUR
0.465
78.8%
DTR
0.4
-25.2%
RAU
0.31
72.2%
MTB
0.012
-25%
BIT
0.005
66.7%
RNX
0.006
-25%
RLC
0.005
66.7%
TEG
0.003
-25%
AON
0.013
62.5%
CDR
0.022
-24.1%
AMX
0.3
53.8%
DRO
4.59
-23.9%
BMG
0.023
53.3%
SLM
0.061
-23.8%
CAE
0.064
52.4%
PSL
0.032
-23.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts